Trial 4B-11-1

An Open-Label, Multi-Center, Randomized Phase II Study Evaluating the Safety and Efficacy of Docetaxel in Combination with Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 or Without Investigational Therapy as Second-Line Therapy in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Bladder, Urethra, Ureter, or Renal Pelvis Following Disease Progression on First-Line Platinum-Based Therapy.

Type: Cancer Therapy
Phase: Phase II
Status: Open to Accrual
Treatments: Chemotherapy: Systemic, Immunotherapy
Randomized: Yes
Defintions of terms and FAQ about clinical trials.

Trial Leaders/Researchers: David Quinn, M.D.
Other Trial Staff: Charlean Ketchens, R.N., Lagrimas Ilagan, D.M., Jolie Solomon, R.N., Roberto Tejada, D.M., Carrie Korn, R.N.

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov

For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3111.